Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.

Francesco RubinoEnrico RepettoCristian GujaElise HardyJenny HanSerge A Jabbour Eleuterio Ferrannini

Published in: Diabetes, obesity & metabolism (2019)

The EXE once weekly + DAPA combination showed stronger effects than EXE once weekly + PLB or DAPA + PLB in ameliorating markers of hepatic steatosis and fibrosis in patients with type 2 diabetes. Prospective trials are needed to validate these findings.

Keyphrases

insulin resistance
high fat diet
metabolic syndrome